🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the battle against increasingly resistant strains of the infection, according to scientists.

An International Challenge

The sexually transmitted infection are increasing around the world, with estimates suggesting in excess of 82 million instances per year. Particularly high rates are reported in the African continent and nations within the WHO's designated area, which includes China and Mongolia to New Zealand. Within England, cases have hit a record high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune advancement in the face of rising global incidence, escalating drug resistance and the very limited treatment choices currently available.”

Medical experts are particularly alarmed about the increase in treatment-resistant strains. The World Health Organization has designated it as a "critical concern". Ongoing monitoring showed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Therapies Gain Clearance

One new antibiotic, also known as a brand name, was cleared by the US FDA in December for treating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Experts believe that targeted use of this new drug will help delay the development of resistance.

Another new antibiotic, originating from the drugmaker GSK, was also approved in close succession. This medication, which is employed against UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to develop it.

“This approval represents a huge turning point in the management of highly resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Research Study Outcomes and Global Access

As per findings detailed in a prominent scientific publication, the new drug eradicated the vast majority of cases of the STI. This puts it on an equal footing with the existing first-line therapy, which uses a dual-drug approach. The study enrolled nearly 1,000 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the ability to make available and distribute the drug in numerous developing nations.

Medical professionals on the front lines have voiced positive views. The availability of a single-dose, oral treatment such as this is hailed as a "critical tool" for gonorrhoea control. This is viewed as crucial to alleviate the strain of the illness for individuals and to prevent the spread of highly drug-resistant gonorrhoea around the world.